Related Experiment Video
Updated: Oct 29, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Alzheimer's genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis
Adeline E Walsh1,2, Benjamin A Davis1, Joshua D Samuels1,3,4
1Center for Brain Immunology and Glia (BIG), Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.
Abstract:
Recent genome-wide association studies have identified numerous Alzheimer's disease (AD) risk genes enriched in microglia, including Crk-associated substrate (Cas) scaffold protein family member 4 (CASS4), which encodes the adaptor protein CASS4. Despite its strong genetic association with AD, the role of CASS4 in disease remains poorly understood. Here, we show that full-body Cass4 deletion in 5xFAD mice increases amyloid-β (Aβ) deposition, neuronal dystrophy, and cognitive deficits. Since microglia are the predominant brain-resident cells expressing Cass4, we investigated its role in microglial responses to Aβ pathology. Loss of CASS4 impaired microglial mobilization to Aβ plaques and reduced plaque compaction. Phosphoproteomic analysis of purified microglia revealed marked disruption of focal adhesion signaling following Cass4 deletion. Consistent with this, CASS4 deficiency abrogated in vivo microglial recruitment to injury and in vitro wound healing responses, two processes that are centrally orchestrated by focal adhesion biology. Together, these findings identify CASS4 as a critical regulator of microglial function and focal adhesion biology and suggest that CASS4 may represent a therapeutic target for AD.
Related Concept Videos
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Parkinson Disease ll: Pathophysiology

